98%
921
2 minutes
20
Summary: The coexistence of neurofibromatosis type 1 (NFT1) and Turner syndrome (TS) has only been reported in a few patients and may represent a diagnostic challenge. We describe the case of a 16-year-old girl, with a prior clinical diagnosis of NFT1, who was referred to Endocrinology appointments for the etiological study of primary amenorrhea. Evaluation of the anterior pituitary function was requested and hypergonadotropic hypogonadism was detected. During the etiological study, a 45X karyotype was found and TS was diagnosed. The fact that NFT1 can also be associated with short stature, short broad neck and hypertelorism was likely responsible for TS being diagnosed in late adolescence. As both TS and NFT1 are relatively common genetic disorders, it is important to be alert to the possibility that the presence of one disease does not invalidate the other.
Learning Points: The concomitant presence of two syndromes in the same patient is unlikely and represents a diagnostic challenge. Some phenotypic characteristics and clinical manifestations may be shared by several syndromes. Some syndromes, such as neurofibromatosis type 1 may have very heterogeneous presentations. It is important to be alert to the characteristics that are not explained by the initial diagnosis. If such features are present, diagnostic work-up must be performed regardless of the initial syndromic diagnosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422264 | PMC |
http://dx.doi.org/10.1530/EDM-22-0226 | DOI Listing |
Neurosci Biobehav Rev
September 2025
Murdoch Children's Research Institute, Melbourne, Australia; Department of Pediatrics, University of Melbourne, Melbourne, Australia.
This systematic review was conducted to provide a comprehensive summary of biopsychosocial factors associated with attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with Neurofibromatosis Type 1 (NF1), and identify key limitations and gaps in the current literature. Systematic literature searches were conducted in Scopus, PsycINFO, Web of Science, PubMed, and ProQuest Dissertations and Theses Global in March 2024. The searches identified 2,345 unique articles.
View Article and Find Full Text PDFJBJS Case Connect
July 2025
Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh, India.
Case: A 12-year-old girl with neurofibromatosis type 1 presented with progressive thoracic scoliosis and neurological deficit. Imaging revealed a dystrophic curve, dorsal syrinx, and tethering of the cord by a plexiform neurofibroma arising from the T7 dorsal ramus. She underwent staged surgery: detethering through T6-T8 laminectomy, followed by posterior spinal deformity correction with Schwab type 2 osteotomies and instrumentation.
View Article and Find Full Text PDFDev Med Child Neurol
September 2025
Murdoch Children's Research Institute, Parkville, VIC, Australia.
Aim: To examine visual engagement to social stimuli and response to joint attention in young children with neurofibromatosis type 1 (NF1) and typically developing peers (controls).
Method: Forty-five preschool children were studied cross-sectionally (mean age [SD] = 4 years 3 months [10 months]), 25 with NF1 and 20 typically developing controls. Participants passively viewed two eye-tracking paradigms.
Cancer Diagn Progn
September 2025
Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.
Background/aim: Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of multiple tumors, including plexiform neurofibromas (PNFs), which often affect the craniofacial region and cause significant functional and aesthetic impairments. This report presents long-term surgical management of a patient with hemifacial diffuse PNF, complicated by the emergence of a rapidly enlarging midfacial tumor.
Case Report: The patient was treated for hemifacial invasive diffuse plexiform neurofibroma.
Front Pharmacol
August 2025
Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of plexiform neurofibromas (PNs), benign yet potentially debilitating tumors with limited treatment options. Selumetinib, a selective MEK1/2 inhibitor, has emerged as a targeted therapy for symptomatic, inoperable PNs in pediatric NF1 patients. Individual variability in drug metabolism, largely influenced by CYP450-mediated pathways, can affect treatment response.
View Article and Find Full Text PDF